Is CGON or MAZE more profitable?

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology N/A -23.33% -22.24% Maze Therapeutics N/A -36.62% -31.78%

Does the media refer more to CGON or MAZE?

In the previous week, Maze Therapeutics had 2 more articles in the media than CG Oncology. MarketBeat recorded 5 mentions for Maze Therapeutics and 3 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.63 beat Maze Therapeutics' score of 0.22 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is COGT or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Maze Therapeutics N/A -36.62% -31.78%

Does the media prefer COGT or MAZE?

In the previous week, Cogent Biosciences had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 7 mentions for Cogent Biosciences and 5 mentions for Maze Therapeutics. Cogent Biosciences' average media sentiment score of 0.48 beat Maze Therapeutics' score of 0.22 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is BLTE or MAZE more profitable?

Belite Bio's return on equity of -13.14% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Maze Therapeutics N/A -36.62% -31.78%

Does the media prefer BLTE or MAZE?

In the previous week, Maze Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Maze Therapeutics and 4 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.49 beat Maze Therapeutics' score of 0.22 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MAZE or LEGN?

In the previous week, Legend Biotech had 9 more articles in the media than Maze Therapeutics. MarketBeat recorded 14 mentions for Legend Biotech and 5 mentions for Maze Therapeutics. Legend Biotech's average media sentiment score of 0.57 beat Maze Therapeutics' score of 0.22 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maze Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Legend Biotech 4 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Is GRFS or MAZE more profitable?

Grifols has a net margin of 5.54% compared to Maze Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Maze Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Maze Therapeutics N/A -36.62% -31.78%

Maze Therapeutics (MAZE) Competitors

$24.86 +0.57 (+2.35%)

Closing price 04:00 PM Eastern

Extended Trading

$24.73 -0.13 (-0.54%)

As of 07:57 PM Eastern

Compare

MAZE vs. CGON, COGT, BLTE, LEGN, and GRFS

Should you buy Maze Therapeutics stock or one of its competitors? MarketBeat compares Maze Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Maze Therapeutics include CG Oncology (CGON), Cogent Biosciences (COGT), Belite Bio (BLTE), Legend Biotech (LEGN), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.

How does Maze Therapeutics compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

26.6% of CG Oncology shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CG Oncology presently has a consensus price target of $81.73, suggesting a potential upside of 50.02%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 165.49%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

CG Oncology's return on equity of -23.33% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	N/A	-23.33%	-22.24%
Maze Therapeutics	N/A	-36.62%	-31.78%

CG Oncology has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

In the previous week, Maze Therapeutics had 2 more articles in the media than CG Oncology. MarketBeat recorded 5 mentions for Maze Therapeutics and 3 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.63 beat Maze Therapeutics' score of 0.22 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,189.30	-$160.99M	-$2.33	N/A
Maze Therapeutics	$167.50M	8.21	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats CG Oncology on 8 of the 15 factors compared between the two stocks.

How does Maze Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, risk, institutional ownership, valuation, dividends, earnings and analyst recommendations.

In the previous week, Cogent Biosciences had 2 more articles in the media than Maze Therapeutics. MarketBeat recorded 7 mentions for Cogent Biosciences and 5 mentions for Maze Therapeutics. Cogent Biosciences' average media sentiment score of 0.48 beat Maze Therapeutics' score of 0.22 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Maze Therapeutics has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Maze Therapeutics	$167.50M	8.21	-$131.12M	-$2.53	N/A

Cogent Biosciences currently has a consensus price target of $43.73, suggesting a potential upside of 35.55%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 165.49%. Given Maze Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Maze Therapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Cogent Biosciences has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market.

Maze Therapeutics' return on equity of -36.62% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Maze Therapeutics	N/A	-36.62%	-31.78%

Summary

Maze Therapeutics beats Cogent Biosciences on 7 of the 11 factors compared between the two stocks.

How does Maze Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Belite Bio has a beta of -1.24, indicating that its stock price is 224% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.26, indicating that its stock price is 126% more volatile than the broader market.

Belite Bio presently has a consensus target price of $203.00, suggesting a potential upside of 47.93%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 165.49%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Maze Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Belite Bio's return on equity of -13.14% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, Maze Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 5 mentions for Maze Therapeutics and 4 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.49 beat Maze Therapeutics' score of 0.22 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Belite Bio has higher earnings, but lower revenue than Maze Therapeutics. Belite Bio is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Maze Therapeutics	$167.50M	8.21	-$131.12M	-$2.53	N/A

Summary

Maze Therapeutics beats Belite Bio on 7 of the 13 factors compared between the two stocks.

How does Maze Therapeutics compare to Legend Biotech?

Maze Therapeutics (NASDAQ:MAZE) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Maze Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maze Therapeutics	N/A	-36.62%	-31.78%
Legend Biotech	-21.98%	-24.92%	-14.87%

Maze Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market.

70.9% of Legend Biotech shares are owned by institutional investors. 5.3% of Maze Therapeutics shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Maze Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Maze Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maze Therapeutics	$167.50M	8.21	-$131.12M	-$2.53	N/A
Legend Biotech	$1.03B	6.50	-$296.80M	-$0.68	N/A

In the previous week, Legend Biotech had 9 more articles in the media than Maze Therapeutics. MarketBeat recorded 14 mentions for Legend Biotech and 5 mentions for Maze Therapeutics. Legend Biotech's average media sentiment score of 0.57 beat Maze Therapeutics' score of 0.22 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maze Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Legend Biotech	4 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Maze Therapeutics presently has a consensus price target of $66.00, suggesting a potential upside of 165.49%. Legend Biotech has a consensus price target of $60.23, suggesting a potential upside of 67.40%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Legend Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Maze Therapeutics and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Maze Therapeutics compare to Grifols?

Grifols (NASDAQ:GRFS) and Maze Therapeutics (NASDAQ:MAZE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability, valuation and media sentiment.

Grifols has higher revenue and earnings than Maze Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.60	$454.82M	$0.19	39.32
Maze Therapeutics	$167.50M	8.21	-$131.12M	-$2.53	N/A

Grifols presently has a consensus target price of $10.00, suggesting a potential upside of 33.87%. Maze Therapeutics has a consensus target price of $66.00, suggesting a potential upside of 165.49%. Given Maze Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Maze Therapeutics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Maze Therapeutics had 4 more articles in the media than Grifols. MarketBeat recorded 5 mentions for Maze Therapeutics and 1 mentions for Grifols. Grifols' average media sentiment score of 1.89 beat Maze Therapeutics' score of 0.22 indicating that Grifols is being referred to more favorably in the media.

Company	Overall Sentiment
Grifols	Very Positive
Maze Therapeutics	Neutral

Grifols has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

Grifols has a net margin of 5.54% compared to Maze Therapeutics' net margin of 0.00%. Grifols' return on equity of 6.21% beat Maze Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Maze Therapeutics	N/A	-36.62%	-31.78%

Summary

Grifols and Maze Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Maze Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MAZE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MAZE vs. The Competition

Export

Metric	Maze Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.34B	$3.28B	$6.45B	$12.42B
Dividend Yield	N/A	2.33%	2.69%	5.29%
P/E Ratio	N/A	17.93	22.30	24.19
Price / Sales	8.21	324.62	581.44	138.36
Price / Cash	N/A	116.27	42.31	57.88
Price / Book	3.37	6.63	9.84	6.72
Net Income	-$131.12M	$24.20M	$3.57B	$337.19M
7 Day Performance	-4.57%	-3.24%	-1.16%	0.48%
1 Month Performance	-8.82%	0.53%	3.85%	5.07%
1 Year Performance	81.99%	47.24%	27.40%	34.25%

Maze Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MAZE Maze Therapeutics	2.9859 of 5 stars	$24.86 +2.3%	$66.00 +165.5%	+100.7%	$1.34B	$167.50M	N/A	121
CGON CG Oncology	2.7987 of 5 stars	$64.25 -0.5%	$81.73 +27.2%	+108.8%	$5.67B	$5.07M	N/A	61
COGT Cogent Biosciences	3.1612 of 5 stars	$32.67 +0.3%	$43.73 +33.8%	+484.0%	$5.58B	N/A	N/A	80
BLTE Belite Bio	2.9641 of 5 stars	$137.30 -4.8%	$203.80 +48.4%	+107.5%	$5.49B	N/A	N/A	10
LEGN Legend Biotech	4.1855 of 5 stars	$29.37 +4.9%	$59.00 +100.9%	+23.7%	$5.43B	$1.14B	N/A	2,965	News Coverage Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MAZE) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Maze Therapeutics (MAZE) Competitors

MAZE vs. CGON, COGT, BLTE, LEGN, and GRFS

How does Maze Therapeutics compare to CG Oncology?

Summary

How does Maze Therapeutics compare to Cogent Biosciences?

Summary

How does Maze Therapeutics compare to Belite Bio?

Summary

How does Maze Therapeutics compare to Legend Biotech?

Summary

How does Maze Therapeutics compare to Grifols?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Maze Therapeutics (MAZE) Competitors

MAZE vs. CGON, COGT, BLTE, LEGN, and GRFS

How does Maze Therapeutics compare to CG Oncology?

Do institutionals and insiders have more ownership in CGON or MAZE?

Do analysts prefer CGON or MAZE?

Is CGON or MAZE more profitable?

Which has more risk & volatility, CGON or MAZE?

Does the media refer more to CGON or MAZE?

Which has higher valuation & earnings, CGON or MAZE?

Summary

How does Maze Therapeutics compare to Cogent Biosciences?

Does the media prefer COGT or MAZE?

Which has higher earnings & valuation, COGT or MAZE?

Do analysts rate COGT or MAZE?

Which has more risk and volatility, COGT or MAZE?

Is COGT or MAZE more profitable?

Summary

How does Maze Therapeutics compare to Belite Bio?

Which has more volatility and risk, BLTE or MAZE?

Do analysts prefer BLTE or MAZE?

Do insiders & institutionals hold more shares of BLTE or MAZE?

Is BLTE or MAZE more profitable?

Does the media prefer BLTE or MAZE?

Which has stronger valuation and earnings, BLTE or MAZE?

Summary

How does Maze Therapeutics compare to Legend Biotech?

Is MAZE or LEGN more profitable?

Which has more volatility and risk, MAZE or LEGN?

Do insiders and institutionals have more ownership in MAZE or LEGN?

Which has preferable earnings and valuation, MAZE or LEGN?

Does the media favor MAZE or LEGN?

Do analysts recommend MAZE or LEGN?

Summary

How does Maze Therapeutics compare to Grifols?

Which has preferable earnings & valuation, GRFS or MAZE?

Do analysts rate GRFS or MAZE?

Does the media favor GRFS or MAZE?

Which has more risk and volatility, GRFS or MAZE?

Is GRFS or MAZE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAZE vs. The Competition

Maze Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools